Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
Фаза 3
Завершено
NCT03260894
| Заболевание | Renal Cell Carcinoma |
|---|
| Фаза | Фаза 3 |
|---|
| Спонсор | Incyte Corporation |
|---|
| Статус | Завершено |
|---|
| Участники | 129 участн. |
|---|
| Вмешательство | Pembrolizumab, Epacadostat, Sunitinib, Pazopanib |
|---|
| Дата начала | 7.12.2017 |
|---|
| Дата завершения | 22.08.2018 |
|---|
| Публикация результатов | 10.09.2019 |
|---|
Кратко
The purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat compared to sunitinib or pazopanib in participants with locally advanced/metastatic renal cell carcinoma (mRCC) with a clear cell component who have not received prior systemic therapy for their mRCC.
Objective Response Rate (ORR) of Pembrolizumab + Epacadostat Versus Standard of Care (SOC)
up to approximately 8 months · percentage of participants
| Pembrolizumab + Epacadostat | 1.6 percentage of participants |
|---|
| SoC (Sunitinib or Pazopanib) | 0.0 percentage of participants |
|---|
| Pembrolizumab + Epacadostat | 29.7 percentage of participants |
|---|
| SoC (Sunitinib or Pazopanib) | 29.2 percentage of participants |
|---|
| Pembrolizumab + Epacadostat | 31.3 percentage of participants |
|---|
| SoC (Sunitinib or Pazopanib) | 29.2 percentage of participants |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.